Results 41 to 50 of about 36,083 (204)
Regulatory feedback on receptor and non-receptor synthesis for robust signaling. [PDF]
, 2020 Elaborate regulatory feedback processes are thought to make biological development robust, that is, resistant to changes induced by genetic or environmental perturbations. How this might be done is still not completely understood.
Lander, Arthur D +4 more
core +1 more source
Miscellanea. Folyóirat-referátumok. OH-KVÍZ [PDF]
, 2016 Diabetológia A DPP-4-gátlók súlyos ízületi fájdalmat okozhatnak – az FDA jelentése (DPP-4 inhibitors for diabetes can cause severe joint pain, FDA says) Robert Lowes, Medscape, Aug 28, 2015.
Apor, Péter +2 more
core +1 more source
Journal of Enzyme Inhibition and Medicinal Chemistry, 2018 Dipeptidyl peptidase 4 (DPP-4) inhibitors are used for the treatment of type-2 diabetes mellitus. Various synthetic inhibitors have been developed to date, and plants containing natural DPP-4 inhibitors have also been identified.
Eisuke Kato +2 more
doaj +1 more source
Frontiers in Pharmacology, 2017 Background and Objectives: Limited research focuses on the risk of ischemic cerebrovascular disease associated with use of dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) in patients with type 2 diabetes mellitus in Taiwan.
Shih-Wei Lai +7 more
doaj +1 more source
Editorial – COVID-19 pandemic: is it time to learn about DPP-4/CD26? [PDF]
CellR4, 2020 The rapid spread of SARS-CoV-2, a novel coronavirus that emerged in late 2019, and the resulting COVID-19 pandemic, has been labeled as a public health emergency of international concern by the World Health Organization.
M. Maia Pinheiro +2 more
doaj +1 more source
Comparative Effectiveness of DPP-4 Inhibitors Versus Sulfonylurea for the Treatment of Type 2 Diabetes in Routine Clinical Practice: A Retrospective Multicenter Real-World Study [PDF]
, 2018 Introduction: DPP-4 inhibitors (DPP4i) and sulfonylureas are popular second-line therapies for type 2 diabetes (T2D), but there is a paucity of real-world studies comparing their effectiveness in routine clinical practice. Methods: This was a multicenter
Avogaro Angelo +10 more
core +1 more source
DPP-4 Inhibitors as Treatments for Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis
Journal of Diabetes Research, 2018 Objective. Several clinical studies have reported the application of dipeptidyl peptidase-4 (DPP-4) inhibitors as treatments for type 1 diabetes mellitus (T1DM).
Qixian Wang +8 more
doaj +1 more source
Cardiovascular Diabetology, 2018 Background Incretin-based therapies including dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon like peptide-1 (GLP-1) receptor agonists are novel medications for type 2 diabetes management.
Ghadeer K. Dawwas +2 more
doaj +1 more source
Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice [PDF]
, 2016 Diabetic patients suffer from a high rate of cardiovascular events and such risk increases with HbA1c. However, lowering HbA1c does not appear to yield the same benefit on macrovascular endpoints, as observed for microvascular endpoints. As the number of
Avogaro, Angelo +4 more
core +3 more sources
Effects of Dipeptidyl Peptidase-4 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis [PDF]
Endocrinology and Metabolism, 2019 BackgroundTo investigate the effects of dipeptidyl peptidase-4 (DPP-4) inhibitors on renal outcomes in patients with type 2 diabetes.MethodsMEDLINE, Embase, and the Cochrane Central Register of Controlled Trials were searched to identify randomized ...
Jae Hyun Bae +5 more
doaj +1 more source